title: Treatment-resistant Churg-Strauss syndrome: progression after five years using rituximab.
authors.forename: María
authors.initials: M
authors.lastname: Martínez-Villaescusa
authors.forename: Aurora
authors.initials: A
authors.lastname: López-Montes
authors.forename: Esperanza
authors.initials: E
authors.lastname: López-Rubio
authors.forename: Lourdes
authors.initials: L
authors.lastname: de la Vara-Iniesta
authors.forename: Marina
authors.initials: M
authors.lastname: Méndez-Molina
authors.forename: Dionisio
authors.initials: D
authors.lastname: Donate-Ortiz
authors.forename: Hyun
authors.initials: H
authors.lastname: Nam-Cha
authors.forename: Carmen
authors.initials: C
authors.lastname: Gómez-Roldán
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001706:Biopsy; D015267:Churg-Strauss Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D004351:Drug Resistance; D005921:Glomerulonephritis / Q000209:etiology / Q000473:pathology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use; D010956:Plasmapheresis; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D012074:Remission Induction; D006435:Renal Dialysis; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D011241:Prednisone; D008775:Methylprednisolone